(Reuters) -Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures picking up pace.
The company’s shares rose more than 4% before the bell.
Investor expectations around the performance of medical device makers have been heightened since last November after a resurgence in demand, as people, especially older adults, opted for medical procedures deferred during the pandemic.
Boston Scientific, which generates most of its revenue from sales of its heart devices such as pacemakers and stents, also makes equipment for diagnosing and treating a range of gastrointestinal and pulmonary conditions.
The company now expects 2024 adjusted earnings per share between $2.29 and $2.34, compared with its previous forecast of $2.23 to $2.27 per share.
Boston Scientific reported first-quarter revenue of $3.86 billion, beating estimates of $3.69 billion, according to LSEG data.
On an adjusted basis, the company earned 56 cents per share, compared with estimates of 51 cents.
(Reporting by Christy Santhosh and Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta)
Comments